Literature DB >> 22543827

Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma.

Ji-Sun Paik1, Won-Kyung Cho, Sung-Eun Lee, Byung-Ock Choi, Seung-Eun Jung, Gyeong-Sin Park, Sung-Hoon Kim, Suk-Woo Yang, Seok-Goo Cho.   

Abstract

In the present study, we evaluated the ophthalmologic outcomes of 24 patients who received chemotherapy and/or radiotherapy for the treatment of non-conjunctival ocular adnexal mucosa-associated lymphoid tissue-type (MALT) lymphoma. Ophthalmologic outcomes were assessed in patients who received chemotherapy and/or radiotherapy from March 2004 until May 2010. Outcomes were determined according to common symptoms following chemotherapy and/or radiotherapy, which consisted of decreased visual acuity, dry eye symptoms, retinopathy, optic neuropathy, increased intraocular pressure, and blepharitis. Nine patients received chemotherapy alone, eight patients received radiotherapy alone, and seven patients received chemotherapy with additional radiotherapy (chemoradiation therapy). Patients treated by chemotherapy alone showed better ophthalmologic outcome scores (mean score, 1.56) than those treated by radiation alone or chemoradiation therapy (mean score, 4.01). In conclusion, the treatment of ocular adnexal lymphoma including radiotherapy showed poor ophthalmologic outcomes due to radiation-induced complications. Recently, many new treatment options have emerged, such as immunotherapy or radioimmunotherapy. In the future study, to select a better treatment modality with fewer complications, well-designed prospective trials with ophthalmologic outcomes are needed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543827     DOI: 10.1007/s00277-012-1469-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  12 in total

1.  Histopathological Features and Ann Arbor Stage in Periocular Lymphoma.

Authors:  Marco Zschoche; Annette Zimpfer; Björn O Scheef; Anselm M Jünemann; Rudolf F Guthoff; Christian Junghanss; Guido Hildebrandt; Steffen Emmert; Andreas Erbersdobler; Günther Kundt; Vinodh Kakkassery
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Choroidal and adnexal extranodal marginal zone B-cell lymphoma: presentation, imaging findings, and therapeutic management in a series of nine cases.

Authors:  P Loriaut; F Charlotte; B Bodaghi; D Decaudin; V Leblond; C Fardeau; L Desjardins; P Lehoang; N Cassoux
Journal:  Eye (Lond)       Date:  2013-04-19       Impact factor: 3.775

3.  Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections.

Authors:  Gustavo Savino; Remo Battendieri; Mariangela Gari; Carmela Grazia Caputo; Luca Laurenti; Maria Antonietta Blasi
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-27       Impact factor: 4.553

4.  Primary Orbital Follicular Lymphoma: A Case Report and Review.

Authors:  G Lakshmi Prasad; Ajay Hegde; Girish Menon; Mary Mathew
Journal:  J Clin Diagn Res       Date:  2017-03-01

Review 5.  Primary extranodal marginal zone B-cell lymphoma with diffuse uveal involvement and focal infiltration of the trabecular meshwork: a case report and review of literature.

Authors:  Xinxiao Gao; Bin Li; Qisheng You; Xiaoyan Peng
Journal:  BMC Ophthalmol       Date:  2015-05-07       Impact factor: 2.209

6.  Primary Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue of the Lacrimal Sac Found with Epiphora: A Case Report.

Authors:  Yoshiyuki Kitaguchi; Yasuhiro Takahashi; Jacqueline Mupas-Uy; Emiko Takahashi; Hirohiko Kakizaki
Journal:  Case Rep Ophthalmol       Date:  2016-09-16

7.  Extranodal Marginal Zone Lymphoma of Ocular Adnexa: Outcomes following Radiation Therapy.

Authors:  Sean Platt; Yahya Al Zahrani; Nakul Singh; Brian Hill; Sheen Cherian; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-02-02

8.  Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients.

Authors:  Barbara Kiesewetter; Julius Lukas; Andreas Kuchar; Marius E Mayerhoefer; Berthold Streubel; Heimo Lagler; Leonhard Müllauer; Stefan Wöhrer; Julia Fischbach; Markus Raderer
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

9.  Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study.

Authors:  Sung-Yong Kim; Suk-Woo Yang; Won-Sik Lee; Jae Wook Yang; Sung Yong Oh; Hee Bae Ahn; Deok-Hwan Yang; Seong Kyu Park; Jee Ho Chang; Hyo Jung Kim; Min Joung Lee; Seok-Goo Cho
Journal:  Oncotarget       Date:  2017-08-02

10.  The clinical features of radiation cataract in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma.

Authors:  Kanae Fukutsu; Satoru Kase; Kan Ishijima; Rumiko Kinoshita; Susumu Ishida
Journal:  Radiat Oncol       Date:  2018-05-16       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.